Coldstream Capital Management
JBIO icon

Coldstream Capital Management’s Jade Biosciences JBIO Stock Holding History

Coldstream Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$262 – 1315
2025
Q1 		$262 Buy
+3
New +$264 ﹤0.01% 3458

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Coldstream Capital Management's JBIO Position: Q2 2025 in Review

Coldstream Capital Management sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 3 shares — an estimated $262 sold.

Coldstream Capital Management first reported a position in JBIO in Q1 2025 and held it in 1 quarter. The position peaked at $262 in Q1 2025. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • Coldstream Capital Management reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 3 Jade Biosciences shares in Q2 2025, an estimated $262.
  • Coldstream Capital Management first reported a position in Jade Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Jade Biosciences position peaked at $262 in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.